Ajanta Pharma logo

Ajanta Pharma financials: balance sheet, profit and loss, cash flow

NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap

Ajanta Pharma Limited · Face value ₹2 · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,508.80up ₹49.10 (1.42%)BSE ₹3,512.40

Share price at the NSE close on 30 Oct 2026. Previous close ₹3,459.70.

30 Oct: open ₹3,479.00, high ₹3,619.90, low ₹3,460.50

52-week range of traded prices to 30 Oct 2026
₹2,430.00Low, 30 Oct 2025₹3,796.00High, 18 Aug 2026
Market cap
₹43,846 Cr236th largest listed
P/E
34.72
P/B
9.02
Dividend yield
1.71%
ROE
27.5%
ROCE
30.3%
Debt to equity
0.02
Volume, NSE
9,52,55826.6% delivered

Ajanta Pharma's financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

10 years at a glance

₹ crore, years to March.Ajanta Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
2,002507Mar 172,131469Mar 182,05538734Mar 192,58846844Mar 202,8906541.6Mar 213,3417131.9Mar 223,7435881.4Mar 234,2098161.5Mar 244,6489202.6Mar 255,4531,056212Mar 26
Peak revenue ₹5,453 Cr, year to Mar 2026; lowest ₹2,002 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
34.6%15.7%34.4%30.9%27.6%26.4%34.6%27.8%20.9%27.8%27.1%25.6%25.3%22.0%18.8%18.1%22.6%21.3%15.7%19.4%19.8%19.4%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.5% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue5,453
  2. Materials and goods−1,184
  3. Employee costs−1,291
  4. Other expenses−1,583
  5. Operating profit1,395
  6. Depreciation−173
  7. Other income+172
  8. One-off items0.0
  9. Finance costs−16
  10. Profit before tax1,378
  11. Tax−322
  12. Net profit1,056

What the company owns

  • Plant, investments and other assets₹2,698 Cr
  • Receivables₹1,854 Cr
  • Inventory₹939 Cr
  • Current investments₹560 Cr
  • Cash and bank₹105 Cr

What pays for it: net worth and liabilities

  • Net worth₹4,527 Cr
  • Other liabilities₹871 Cr
  • Owed to suppliers₹544 Cr
  • Borrowings₹212 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Ajanta Pharma quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 5 MaySep 2026Twelve monthsFiled 30 Oct
Revenue from operations2,0022,1312,0552,5882,8903,3413,7434,2094,6485,4536,217
1,3131,4721,4891,9051,8912,4122,9593,0373,3894,0584,530
Materials and goods bought4154063836566458321,0501,0671,0711,1841,304
Employee costs2953764314865486467859001,0901,2911,436
Other expenses6036906757636989341,1241,0701,2281,5831,790
Operating profit before depreciation6896585666839999297831,1721,2601,3951,687
Operating margin34.4%30.9%27.6%26.4%34.6%27.8%20.9%27.8%27.1%25.6%27.1%
Materials, % of revenue20.7%19.1%18.7%25.3%22.3%24.9%28.1%25.3%23.0%21.7%21.0%
Employee costs, % of revenue14.8%17.7%21.0%18.8%19.0%19.3%21.0%21.4%23.4%23.7%23.1%
Other expenses, % of revenue30.1%32.4%32.8%29.5%24.1%27.9%30.0%25.4%26.4%29.0%28.8%
Depreciation and amortisation61607296116125131135144173181
Operating profit after depreciation6285994945888828046521,0371,1151,2221,506
Other income2424219226116998595172195
Finance costs3011281067211613
Profit before one-off items and tax6486235146689009097451,1141,1891,3781,688
One-off items000−40000000
Profit before tax6486235146649009097451,1141,1891,3781,688
141154127196246197157298269322425
5074693874686547135888169201,0561,263
Other comprehensive income––−36−6−815122921
Total comprehensive income––3844736477056038179221,0851,284
Net margin25.3%22.0%18.8%18.1%22.6%21.3%15.7%19.4%19.8%19.4%20.3%

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 5 MaySep 2026Half yearFiled 30 Oct
2,2452,5992,9963,2643,3883,5673,7904,5274,858
Share capital181817172525252525
Reserves2,2282,5812,9783,2473,3633,5423,7654,5024,833
344422113212104
3786066496471,1398959961,4161,343
73114134144152175229212224
Liabilities going with businesses held for sale–––––1–––
2,6963,3193,7794,0564,6794,6385,0156,1556,425
1,5151,6771,7511,7911,8451,9072,1722,4192,602
1,1811,6422,0282,2642,8252,7222,8303,7353,823
Net debt−131−229−384−332−840−459−612−453−576
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 5 MaySep 2026Half year
5765627927851,157529750
8078019431,0971,480888956
−209−20067−100179−653−65
Receivables31−270−11−17980−591−50
Inventories−271−26−22−12−75−31−28
Payables11−489741−89129
Other working capital20143351181−122−16
Tax paid−230−239−151−312−323−359−207
Capital spending172149174152318365259
Free cash flow405413617633839164490
−282−74−56065−377−429−249
−318−460−108−1,051−733−168−515
Dividends paid838290642349350400
Shares bought back135354138935300
Shares issued0000000
Net change in cash−2428124−20147−68−14
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Ajanta Pharma dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 5 May
₹38.39₹35.51₹29.31₹35.73₹50.06₹54.97₹45.89₹64.82₹73.56₹84.53
As stated that year₹57.59₹53.26₹43.97₹53.60₹75.09₹82.45₹45.89₹64.82₹73.56₹84.53
₹38.39₹35.50₹29.31₹35.73₹50.06₹54.97₹45.89₹64.77₹73.53₹84.51
₹8.67–₹6.00₹8.67₹6.33₹6.33₹7.00₹51.00₹28.00₹28.00
––₹170.67₹197.56₹229.68₹253.49₹268.14₹282.34₹302.38₹361.16
Dividend payout22.6%–20.6%24.4%12.6%11.4%15.0%78.9%38.1%33.2%
Shareholder yield––––1.4%2.8%0.6%3.7%2.1%1.0%
Market cap at the year end (₹ crore)15,49412,2379,11211,92315,50615,66915,48828,09032,76435,046
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Ajanta Pharma PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 5 May
Revenue growth15.9%6.5%−3.5%25.9%11.7%15.6%12.0%12.5%10.4%17.3%
Operating profit growth–−4.4%−14.0%20.6%46.1%−6.9%−15.7%49.6%7.5%10.7%
Net profit growth26.3%−7.5%−17.4%20.9%39.8%9.0%−17.5%38.8%12.8%14.7%
Earnings per share growth26.2%−7.5%−17.4%21.9%40.1%9.8%−16.5%41.3%13.5%14.9%
––17.1%19.3%23.4%22.8%17.7%23.5%25.0%25.4%
–––2.2 pts4.1 pts−0.6 pts−5.1 pts5.8 pts1.5 pts0.4 pts
From the net margin–––−0.5 pts4.9 pts−1.3 pts−6.0 pts4.2 pts0.5 pts−0.6 pts
From asset turnover–––2.1 pts−1.3 pts1.0 pts0.1 pts1.2 pts1.6 pts0.3 pts
From borrowing–––0.6 pts0.5 pts−0.3 pts0.8 pts0.5 pts−0.5 pts0.6 pts
Return on capital employed––21.7%22.2%29.4%24.6%19.2%29.0%29.4%25.8%
Cash conversion––––88.1%78.9%134.7%96.2%125.7%50.1%
Interest cover179.91,460.5426.249.3106.778.8111.7143.853.875.8
Debt to equity––0.020.020.000.000.000.000.000.05
Receivable days––821099311110310893124
Inventory days––415276434347283283308289
Payable days––214202212143147159155168
Cash conversion cycle, days––282184315315240233246246
Working capital days––1191141261408211996125
Asset turnover––0.760.860.810.850.860.900.960.98
Assets per rupee of net worth––1.201.241.271.251.311.341.311.34
Sales per rupee of plant––1.751.902.022.352.663.042.863.16
Capital spending to depreciation––––1.481.191.331.132.212.11
Plant being built, % of plant in use––22.3%9.7%7.6%10.7%14.9%18.5%10.8%14.9%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
18.9%
Cash from operations against operating profit
37.9%
Measure10 years5 years3 years
Revenue growth, yearly rate12.2%13.5%13.4%
Profit growth, yearly rate10.2%10.1%21.6%
Return on equity, average–22.9%24.6%
Return on capital employed, average–25.6%28.1%
Operating margin, average28.3%25.9%26.8%
Net margin, average20.2%19.1%19.5%
Asset turnover, average–0.910.95
Cash conversion cycle, days, average–256242
Interest cover, average268.792.891.1
Debt to equity, average–0.010.02

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations3,8252,471529
Cash from investing−1,374−740−429
Cash from financing−2,520−1,952−168
Capital spending1,159835365
Dividends paid1,5131,341350
Shares bought back1,0987420
Shares issued for cash000
Borrowings raised211211209
Borrowings repaid000

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––665776
Altman Z-scorePublished threshold 1.81––14.9912.9015.0414.969.8719.0419.3216.07
Beneish M-scorePublished threshold −1.78––––−2.42−1.98−2.79−2.14−2.78−1.75
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––10.145.748.15−0.742.8917.11
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.991.011.180.89
Receivables growth less revenue growthOur threshold 0 percentage points–––42.83−16.4222.49−8.385.52−15.5839.43
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−57.2356.26−25.81−23.100.028.72−6.72
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−1.221.39−0.47−0.521.38−0.572.77
Assets under construction, years of additionsOur threshold 2 years of additions–––0.460.581.271.832.300.460.94
Effective tax ratePublished threshold 17.16 per cent21.8124.7224.7529.5627.3621.6421.1026.7322.6023.35
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−4.650.80−1.29−4.56−2.71
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
14 Aug 2026CARE Ratings LimitedFund-based/Non-fund-based-LT/STCARE AA+ / CARE A1+Review, Re-affirmStable62.50
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.